EPIPHANY BIOSCIENCES, INC.

Medtech

Multi-antigen serological ELISA assay for detection of KSHV antibodies in blood samples

Grants
$3.0M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
8
1 granted · 7 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Improved Diagnosis of Kaposi's Sarcoma-Associated Herpesvirus Infection$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · Improved Diagnosis of Kaposi's Sarcoma-Associated Herpesvirus Infection$1,000,000
Federal grantDepartment of Health and Human Services · Phase II · Improved Diagnosis of Kaposi's Sarcoma-Associated Herpesvirus Infection$1,000,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1797GAIA MEDICAL INSTITUTE, LLC, THE——
1798PRECISION MEMBRANES, LLC——
1799LED RADIOFLUIDICS CORP——
1800EPIPHANY BIOSCIENCES, INC.——
1801CLEARNANO INC——
1802MABDX, INC.——
1803HEARTVISTA, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 8
  • Method Of Treating Viral Infectionsapplication
  • Valomaciclovir Polymorphsgranted
  • Valomaciclovir Polymorphsapplication
  • Valomaciclovir Polymorphsapplication
  • Use Of Antiviral Agents, Composition Of Matter, Combination Preparations/agents To Treat Chronic Diseases Associated With Epstein-barr Virus And Other Human Herpes Virusesapplication
  • Diagnosis Of Kaposi's Sarcoma-associated Herpesvirus (kshv) Infectionapplication
  • Method Of Treating Infectious Mononucleosis With Acyclic Nucleotide Derivativesapplication
  • Treatment And/or Prevention Of Multiple Sclerosisapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.